Durgical
EN
Open the app

MDS/MPN overlap: CMML, JMML and atypical CML

  • Look-alikes compared

Some marrow cancers both overproduce and produce badly. Recognising the overlap explains why the count is high, the cells look wrong and the spleen is big.

Updated

What it is

Myelodysplastic/myeloproliferative neoplasms are clonal marrow diseases with features of both halves at once: high counts and a big spleen (the MPN side) together with dysplasia and often cytopenias of other lines (the MDS side), with fewer than 20% blasts. Chronic myelomonocytic leukaemia (CMML) is the commonest, in older adults; juvenile myelomonocytic leukaemia (JMML) is its childhood counterpart, driven by the RAS pathway; atypical CML (renamed MDS/MPN with neutrophilia in the 2022 WHO classification) makes too many dysplastic neutrophils without BCR::ABL1; and MDS/MPN with SF3B1 mutation and thrombocytosis combines ring sideroblasts with a high platelet count.

The difference in one line

  • CMML: persistent monocytes of at least 0.5 × 10⁹/L and at least 10% of white cells under the 2022 classifications (older criteria used 1 × 10⁹/L), with fewer than 20% blasts and no BCR::ABL1.
  • CMML is split into a dysplastic type (lower white count, cytopenias) and a proliferative type (white count of 13 × 10⁹/L or more, big spleen, skin and serous infiltrates); TET2, SRSF2, ASXL1 and RAS mutations are typical.
  • JMML: children usually under 6, often infants; monocytosis, big liver and spleen, rash, high fetal haemoglobin, monosomy 7 in some; driven by PTPN11, NRAS, KRAS, NF1 or CBL, with links to Noonan syndrome and neurofibromatosis type 1.
  • Atypical CML: high white count with dysplastic neutrophils and at least 10% immature granulocytes, few monocytes and basophils, no BCR::ABL1; SETBP1 and ASXL1 mutations are common; it differs from CML (basophilia, BCR::ABL1) and chronic neutrophilic leukaemia (CSF3R, mature cells without dysplasia).
  • All can progress to AML; the risk is highest with adverse mutations such as ASXL1 and with rising blasts.
  • Allogeneic stem cell transplant is the only curative treatment; hypomethylating agents and cytoreduction with hydroxycarbamide control disease in others.

The overlap neoplasms side by side

FeatureCMMLJMMLAtypical CMLMDS/MPN-SF3B1-T
Typical patientOlder adult, more often menInfant or young child, sometimes with Noonan or NF1Older adultOlder adult
The cell that floods the bloodMonocytesMonocytes with immature myeloid cells and nucleated red cellsDysplastic neutrophils and their precursorsPlatelets
Key geneticsTET2, SRSF2, ASXL1, RASPTPN11, NRAS, KRAS, NF1, CBL; monosomy 7SETBP1, ASXL1; BCR::ABL1 negativeSF3B1 with JAK2 V617F in many
Other clueBig spleen, skin infiltrates, autoimmune featuresHigh fetal haemoglobin, rash, GM-CSF hypersensitivityFew basophils and monocytesRing sideroblasts in the marrow, anaemia
Treatment principleObservation if low risk; hypomethylating agent or hydroxycarbamide; transplant if fit and high riskAllogeneic transplant for most; some CBL and NRAS cases regress on their ownTransplant if fit; hypomethylating agent or hydroxycarbamide otherwiseTreat anaemia (ESA, luspatercept) and thrombosis risk

In clinical practice

  • An older adult with persistent monocytosis, a big spleen and a low platelet count, without infection or inflammation to explain it, needs a smear and marrow for CMML.
  • Reactive monocytosis (tuberculosis, endocarditis, recovery from neutropenia, steroids) is far more common than CMML and is excluded first.
  • A toddler with a big spleen, rash, monocytosis and a very high fetal haemoglobin is JMML until proven otherwise; café-au-lait spots or Noonan features add weight.
  • A high white count with dysplastic, poorly granulated neutrophils and no basophilia should not be labelled CML until BCR::ABL1 testing is negative and atypical CML is considered.
  • Autoimmune and inflammatory conditions (vasculitis, polychondritis, arthritis) accompany CMML in a minority of patients.

How it is confirmed

  • Repeat counts to show the monocytosis persists; smear review for dysplasia, promonocytes and blasts.
  • BCR::ABL1, plus PDGFRA, PDGFRB and FGFR1 rearrangements when eosinophils are high, to exclude neoplasms with targeted treatment.
  • Marrow aspirate and biopsy with karyotype and a myeloid gene panel (TET2, SRSF2, ASXL1, RAS, SETBP1, SF3B1, JAK2).
  • Flow cytometry of blood monocytes: an excess of classical monocytes supports CMML over reactive monocytosis.
  • JMML: fetal haemoglobin for age, karyotype for monosomy 7 and RAS-pathway gene testing, including germline testing for Noonan, NF1 and CBL syndromes.

Common traps

  • Calling persistent monocytosis in an older adult reactive without a smear: CMML can hide behind a normal total white count
  • Diagnosing CML from a high white count and big spleen alone: atypical CML and CMML are BCR::ABL1 negative and do not respond to TKIs
  • Missing JMML because a toddler's big spleen and fever look like infection: a very high fetal haemoglobin and monocytosis point the other way
  • Treating every overlap neoplasm as MDS: the proliferative features (high counts, big spleen) need cytoreduction too
  • Forgetting PDGFR rearrangements when eosinophils are high: those neoplasms respond very well to imatinib

Test yourself

Think of the answer, then tap the question to see it.

A 74-year-old man has had monocytes around 2 × 10⁹/L for six months, a spleen tip and mild thrombocytopenia; no infection is found. Which diagnosis and which test next?

Suspected CMML: marrow aspirate and biopsy with karyotype and a myeloid gene panel (TET2, SRSF2, ASXL1), plus BCR::ABL1 to exclude CML.

A 14-month-old has a big spleen, a rash, monocytosis and a fetal haemoglobin far above that expected for age. Which disease is likely, and what is the usual curative treatment?

Juvenile myelomonocytic leukaemia, a RAS-pathway neoplasm; allogeneic stem cell transplant cures most patients.

Why does a patient with a high white count, dysplastic neutrophils and no basophilia fail to respond to a tyrosine kinase inhibitor given for 'CML'?

It was atypical CML, which lacks BCR::ABL1; the drug's target is absent, so it cannot work.

What makes CMML an 'overlap' neoplasm rather than pure MDS or pure MPN?

It combines myeloproliferative features (monocytosis, big spleen, sometimes a high white count) with myelodysplastic ones (dysplasia and cytopenias), in the same clone.

Add to my cards (4)

Elsewhere in DurgiPedia

Connections

← All of haematology

Educational content; it does not replace assessment by a doctor or your institution's protocols. It contains no doses.

Sources: Myelodysplastic/Myeloproliferative Neoplasms Treatment (PDQ®)–Health Professional Version (National Cancer Institute, 2025); Childhood Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version (National Cancer Institute, 2025); Myelodysplastic Syndrome (StatPearls (NCBI Bookshelf), 2022).

Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake

Representative model, for educational purposes only.